Improving treatment for advanced prostate cancer
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
This research explores a new way to make current prostate cancer treatments work better for patients whose cancer has become resistant to standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11123183 on NIH RePORTER |
What this research studies
Many men with prostate cancer receive treatments that target the androgen receptor, which helps slow tumor growth. However, over time, the cancer often becomes resistant to these treatments. This project aims to understand how combining existing androgen receptor therapies with a different drug, carotuximab, could overcome this resistance. We believe that carotuximab can block specific signals that allow prostate cancer cells to survive and grow even when standard treatments are used. The goal is to find a more effective treatment option for advanced prostate cancer.
Who could benefit from this research
Good fit: This research is most relevant for patients with prostate cancer that has become resistant to standard androgen receptor-targeting treatments.
Not a fit: Patients whose prostate cancer is still responding well to initial androgen receptor therapies may not directly benefit from this specific research at this stage.
Why it matters
Potential benefit: If successful, this approach could offer a new treatment strategy for patients with castration-resistant prostate cancer, potentially extending the effectiveness of their therapy.
How similar studies have performed: A recent phase 2 trial has already shown that combining androgen receptor inhibitors with carotuximab is feasible.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Bhowmick, Neil a. — Cedars-Sinai Medical Center
- Study coordinator: Bhowmick, Neil a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.